No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
XTL Biopharmaceuticals | 20-F: FY2024 Annual Report
XTL Biopharmaceuticals: Shlomo Shalev to Continue as Chmn of Bd >XTLB
Press Release: XTL Names Mr. Noam Band as Its New Chief Executive Officer
X T L Biopharmaceuticals Earlier Announced Definitive Exclusive Sublicense Agreement With Biossil
XTL Biopharmaceuticals Reports Financial Results Amid Regional Unrest
XTL Biopharmaceuticals Resolves Dispute With Social Proxy